AZN acquires GRCL for $10.00/ADS cash+CVR—a 62% premium to Friday’s close (excluding the CVR): https://www.businesswire.com/news/home/20231225813821/en The nominal deal value (excluding the CVR) is $1.0B. AZN is evidently not concerned about the FDA investigation into CAR-T risk of secondary lymphoma (#msg-173310477, #msg-173335665).